STOCK TITAN

Optimus Healthcare (OTC: OHCS) settles $4.4M debt and prepares full shutdown

(Very High)
(Neutral)
Form Type
8-K

Rhea-AI Filing Summary

Optimus Healthcare Services, Inc. outlines its final wind down after a prior strategic review found no viable alternatives to fund operations or cure defaults under its senior secured convertible notes. The company previously repaid a secured loan from JP Morgan Chase Bank and kept a small team to manage regulatory obligations and transition patient care from oncology trials.

On July 14, 2026, Optimus agreed with its first‑priority secured lender, Arena Investors, LP as agent for noteholders, to settle $4.4 million in secured debt plus accrued interest. The company will deliver its remaining cash, after essential wind‑down expenses, to the lender. After a final payment expected on or about July 31, 2026, the notes will be deemed terminated, the company and its officers and directors will receive a release, operations will cease, bank accounts will be closed, and all directors and officers will resign effective August 5, 2026.

Positive

  • None.

Negative

  • Operations to cease: After a final payment expected on or about July 31, 2026, the company’s operations will cease and its bank accounts will be closed as part of the wind down.
  • All leadership resigning: All directors and officers will resign effective August 5, 2026, leaving no continuing management team after completion of the wind down.
  • Remaining cash to secured lender: The company agreed to deliver its remaining cash, after wind‑down expenses, to its first‑priority secured lender to settle $4.4 million of secured debt plus accrued interest.
Item 2.05 Costs Associated with Exit or Disposal Activities Financial
The company committed to an exit plan involving layoffs, facility closures, or restructuring charges.
Secured debt settled $4.4 million Outstanding secured debt under senior secured convertible notes to be settled per July 14, 2026 agreement
Effective date of forbearance amendment April 14, 2025 Effective Date of the fourth amendment to the forbearance agreement regarding specified events of default
Forbearance period end date April 30, 2025 Latest date through which the agent and purchasers agreed to forbear from exercising remedies on specified defaults
Final payment and cessation date July 31, 2026 On or about this date, final payment to agent is expected; notes deemed terminated and operations will cease
Officer and director resignation date August 5, 2026 Effective date on which all directors and officers will resign as part of the final wind down
forbearance agreement financial
"entered into the fourth amendment to the forbearance agreement"
A forbearance agreement is a temporary deal between a borrower and a lender where the lender agrees to delay or reduce payments instead of declaring a default; think of it as a pause button on a loan while both sides work out a longer-term fix. It matters to investors because it affects a company’s short-term cash flow and the likelihood of loan losses or restructuring, which can change credit risk and share value.
senior secured convertible notes financial
"purchasers of the Company’s senior secured convertible notes"
A senior secured convertible note is a loan a company issues that sits near the top of its repayment order (senior), is backed by specific assets as collateral (secured), and can be swapped into company shares later (convertible). For investors this matters because it combines lower risk of repayment and legal protection from the collateral with the upside of converting into equity—so it affects both the safety of debt holders and potential dilution for shareholders.
Qualified Subsequent Financing financial
"deadline for the consummation of the Qualified Subsequent Financing"
Amended and Restated Registration Rights Agreements regulatory
"the definition of “Filing Date” in the Amended and Restated Registration Rights Agreements"
reduction in force financial
"the Board approved certain wind down initiatives, including a reduction in force"
A reduction in force is an organized cutback in a company's workforce—commonly known as layoffs—intended to lower costs or reshape operations. Like trimming a household budget or pruning a garden, it can improve long-term financial health but often brings one-time costs, reduced capacity, and morale or execution risks that can affect revenue, expenses, and the company’s stock performance. Investors watch these moves for signals about future profitability and operational stability.
wind down financial
"determined to initiate the wind down of the Company’s operations"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What did Optimus Healthcare Services (OHCS) decide in the July 14, 2026 agreement?

Optimus Healthcare entered an agreement with its first‑priority secured lender to settle $4.4 million in secured debt plus accrued interest. The company will deliver its remaining cash, after necessary wind‑down expenses, to the lender as part of its plan to fully wind down operations.

How much secured debt is Optimus Healthcare (OHCS) settling under this arrangement?

The company is settling $4.4 million in outstanding secured debt under its senior secured convertible notes, plus accrued interest. This settlement is part of a broader wind‑down plan following unsuccessful strategic alternatives and an inability to cure specified defaults under the notes.

When will Optimus Healthcare (OHCS) cease operations under the wind‑down plan?

After a final payment to its agent expected on or about July 31, 2026, Optimus Healthcare’s operations will cease. At that point, its bank accounts will be closed as it completes the final stages of its previously approved wind down of business activities.

What happens to Optimus Healthcare’s (OHCS) directors and officers as part of the wind down?

All of the company’s directors and officers will resign effective August 5, 2026. This follows completion of the final wind‑down steps, including ceasing operations and closing bank accounts after the last payment to the company’s first‑priority secured lender.

How did Optimus Healthcare (OHCS) address its other secured obligations before this debt settlement?

In connection with its wind‑down initiatives, Optimus Healthcare paid in full the outstanding balance on a secured loan from JP Morgan Chase Bank. It then focused on resolving obligations under its senior secured convertible notes via the July 14, 2026 settlement agreement.

What role do employees play in Optimus Healthcare’s (OHCS) wind down?

The company implemented a reduction in force but retained a core group of employees to execute an orderly wind down. Their work includes handling regulatory aspects of transitioning patient care in existing oncology trials and supporting efforts to maximize remaining business and asset value.
false 0001892025 0001892025 2026-07-14 2026-07-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 14, 2026

 

Optimus Healthcare Services, Inc.

(Exact Name of Registrant as Specified in Its Charter)

 

Florida   333-261849   65-0181535

(State or other jurisdiction

of incorporation)

  (Commission File Number)  

(IRS Employer

Identification No.)

 

1400 Old Country Road, Suite 306

Westbury, New York

  11590
(Address of Principal Executive Offices)   (Zip Code)

 

(516) 806-4201

(Registrant’s Telephone Number, Including Area Code)

 

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act: None.

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

 

 

 

Item 2.05 Costs Associated with Exit or Disposal Activities.

 

As disclosed in our Current Report on Form 8-K filed on April 16, 2025, on April 14, 2025 (the “Effective Date”), Optimus Healthcare Services, Inc. (the “Company”) entered into the fourth amendment to the forbearance agreement (the “Amendment”) by and among the Company and Arena Investors, LP, as agent (“Agent”) for the purchasers of the Company’s senior secured convertible notes (collectively, the “Purchasers”) issued in May 2021 (the “May 2021 Notes”) and June 2022 (the “June 2022 Notes” and collectively with the May 2021 Notes, the “Notes”), pursuant to which, among other things, (i) Section 1(b) of the Forbearance Agreement was amended such that the Agent and the Purchasers agreed to forbear from exercising their rights and remedies with respect to the Specified Events of Default (as defined in the Amendment) under the Notes until that date which is the earliest to occur of: (a) April 30, 2025; (b) the date on which any event of default under the Notes (other than the Specified Events of Default) occurs; and (c) the date on which the Company or any of its subsidiaries fails to comply with any term set forth in the Forbearance Agreement; (ii) the deadline for the consummation of the Qualified Subsequent Financing restructuring milestone was amended from February 28, 2025 to April 30, 2025 and (iii) the definition of “Filing Date” in the Amended and Restated Registration Rights Agreements (as defined in the Amendment) was amended such that the Company agreed to file a registration statement for such securities on the 45th calendar day following the date the Company’s independent public accountants have completed their audit for the fiscal year ended December 31, 2024 and the Company has filed its Annual Report on Form 10-K including such financial statements, or if later, July 31, 2025.

 

As previously announced in our Current Report on Form 8-K filed with the SEC on June 9, 2025, Management started a review of all its strategic alternatives, inclusive of potential new investors, an extension of time under its current Forbearance Agreement, and if the above were unsuccessful, the potential sale or curtailment of some or all of its operations. As of the date of our Current Report on Form 8-K filed with the SEC on September 11, 2025, the Board had completed its strategic review of the Company and determined to initiate the wind down of the Company’s operations given there were no other alternatives to provide the Company ongoing cash to operate its business and it was unable to cure the Specified Defaults under the Notes.

 

In connection with these decisions, the Board approved certain wind down initiatives, including a reduction in force. The Company has maintained a core group of employees necessary to implement an orderly wind down of the Company, including all regulatory aspects of transitioning patient care under existing oncology trials, and support its efforts to maximize the value of the Company’s remaining business and assets. In connection with the wind down, the Company paid in full the outstanding balance on a secured loan from JP Morgan Chase Bank.

 

On July 14, 2026, with the unanimous approval of the Company’s Board of Directors, the Company entered into an agreement with its first priority secured lender (Agent and Purchasers) to settle its outstanding secured debt of $4.4 million plus accrued interest on the Notes and resolve all outstanding claims by Agent and Purchasers under those Notes. As part of the agreement, the Company has agreed to deliver to Agent and Purchasers the remaining cash of the Company, after payment of operating expenses necessary to effectuate the wind down. Upon the final payment to Agent on July 31, 2026, Agent and Purchasers will deem the Notes terminated, and the Company and its officers and directors will receive a release from Agent and Purchasers.

 

After its final payment to Agent and Purchasers on or about July 31, 2026, the Company’s operations will cease and its bank accounts will be closed.

 

In conjunction with its final wind down steps, all of the Company’s Directors and Officers will resign effective August 5, 2026.

 

Cautionary Notes Regarding Forward Looking Statements

 

This Current Report on Form 8-K may contain forward-looking statements regarding future events and our future results that are subject to the safe harbors created under the Private Securities Litigation Reform Act of 1995. These statements reflect the beliefs and assumptions of the Company’s management as of the date hereof. Words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “project,” “seek,” “should,” “target,” “will,” “would,” variations of such words, and similar expressions are intended to identify forward-looking statements, including among others, statements regarding potential strategic alternatives, including capital raises, sale transaction options, restructuring activities and other alternatives. Readers are cautioned that these forward-looking statements are only predictions and are subject to risks, uncertainties and assumptions that are difficult to predict. The Company’s actual results could differ materially and adversely from those expressed in or contemplated by the forward-looking statements. Factors that could cause actual results to differ include, but are not limited to, statements concerning the Board’s strategic review; the perceived benefits and timing of the wind down; the Company’s plans and expected timing with respect to the reduction in workforce; the timeline in which the Company expects to be able to wind down its operations; and other risk factors contained in the Company’s SEC filings available at www.sec.gov, including without limitation, the Company’s annual report on Form 10-K, quarterly reports on Form 10-Q and subsequent filings. In addition, additional or unforeseen effects from the global economic climate may give rise to or amplify many of these risks. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date on which they are made. There can be no assurance that the actual results or developments anticipated by the Company will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, the Company. Therefore, no assurance can be given that the outcomes stated in such forward-looking statements will be achieved. The Company undertakes no obligation to update or revise any forward-looking statements for any reason.

 

Exhibit No.   Description
     
10.1   Wind-Down and Distribution Agreement, dated July 14, 2026

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL document)

  

-1-

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

OPTIMUS HEALTHCARE SERVICES, INC.  
   
By: /s/ Cliff Saffron  
  Cliff Saffron  
  Interim Chief Executive Officer and General Counsel  
   
Dated: July 17, 2026  

 

-2-

 

Filing Exhibits & Attachments

4 documents